Antiantibodies to Cardiac Troponin Associate with Higher Initial Concentrations and Longer Release of Troponin I in Acute Coronary Syndrome Patients

BACKGROUND: Cardiac troponin (cTn) is an established marker of myocardial infarction. Pronounced heterogeneity and the minute amounts released into the circulation constitute significant challenges for cTn detection. Recently, autoantibody formation to cTn was shown to be common and to interfere with immunoassay performance. In this study, we investigated cTn autoantibodies and cardiac troponin I (cTnI) in acute coronary syndrome (ACS) patients over a 1-year period after the index event.

[1]  E. Vanninen,et al.  Clinical significance of troponin I efflux and troponin autoantibodies in patients with dilated cardiomyopathy. , 2008, Journal of Cardiac Failure.

[2]  N. Brunetti,et al.  Increased troponin levels in nonischemic cardiac conditions and noncardiac diseases. , 2008, Journal of interventional cardiology.

[3]  Noel R Rose,et al.  Genetic complexity of autoimmune myocarditis. , 2008, Autoimmunity reviews.

[4]  A. Jaffe,et al.  National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine practice guidelines: Analytical issues for biomarkers of heart failure. , 2008, Circulation.

[5]  J. Todd,et al.  Ultrasensitive flow-based immunoassays using single-molecule counting. , 2007, Clinical chemistry.

[6]  L. Wallentin,et al.  Persistent Cardiac Troponin I Elevation in Stabilized Patients After an Episode of Acute Coronary Syndrome Predicts Long-Term Mortality , 2007, Circulation.

[7]  K. Nagata,et al.  Diversity of the elevation of serum cardiac troponin I levels in patients during their first visit to the emergency room. , 2007, Circulation journal : official journal of the Japanese Circulation Society.

[8]  M. Andrassy,et al.  Cardiac Troponin I but Not Cardiac Troponin T Induces Severe Autoimmune Inflammation in the Myocardium , 2006, Circulation.

[9]  A. Wu.  Cardiac troponin: friend of the cardiac physician, foe to the cardiac patient? , 2006, Circulation.

[10]  P. Porela,et al.  Comparison of cardiac troponin I immunoassays variably affected by circulating autoantibodies. , 2005, Clinical chemistry.

[11]  K. Pulkki,et al.  Negative interference in cardiac troponin I immunoassays by circulating troponin autoantibodies. , 2005, Clinical chemistry.

[12]  K. Pettersson,et al.  Autoantibodies against cardiac troponins. , 2005, The New England journal of medicine.

[13]  Kim Pettersson,et al.  An interfering component in cardiac troponin I immunoassays-Its nature and inhibiting effect on the binding of antibodies against different epitopes. , 2004, Clinical biochemistry.

[14]  Yoshimasa Tanaka,et al.  Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice , 2003, Nature Medicine.

[15]  H. Alfthan,et al.  Negative interference in cardiac troponin I immunoassays from a frequently occurring serum and plasma component. , 2003, Clinical chemistry.

[16]  M. Nieminen,et al.  Effect of 3 Months of Antimicrobial Treatment With Clarithromycin in Acute Non–Q-Wave Coronary Syndrome , 2002, Circulation.

[17]  A. Katrukha,et al.  Biochemical Factors Influencing Measurement of Cardiac Troponin I in Serum , 1999, Clinical chemistry and laboratory medicine.

[18]  L. Voipio‐Pulkki,et al.  Degradation of cardiac troponin I: implication for reliable immunodetection. , 1998, Clinical chemistry.

[19]  K. Pulkki,et al.  Troponin I is released in bloodstream of patients with acute myocardial infarction not in free form but as complex. , 1997, Clinical chemistry.

[20]  F. Van de Werf,et al.  Serum C-reactive protein and infarct size in myocardial infarct patients with a closed versus an open infarct-related coronary artery after thrombolytic therapy. , 1993, European heart journal.